

AN INTERNET-BASED SYMPTOM QUESTIONNAIRE THAT
IS RELIABLE, VALID, AND AVAILABLE TO
PSYCHIATRISTS, NEUROLOGISTS AND
PSYCHOLOGISTS

C. Thomas Gualtieri MD

North Carolina Neuropsychiatry Clinics

Chapel Hill & Charlotte

Dr Gualtieri
NC Neuropsychiatry
400 Franklin Square
1829 East Franklin Street
Chapel Hill NC 27514
919 933 2000 x 106
919 933 2830 fax
tg@ncneuropsych.com

Abstract

The Neuropsych Questionnaire (NPQ) addresses two important clinical issues: how to screen patients for a wide range of neuropsychiatric disorders, quickly and efficiently; and how to acquire independent verification of a patient's complaints. The NPQ is available over the Internet in adult and pediatric versions. The adult version of the NPQ consists of 207 simple questions about common symptoms of neuropsychiatric disorders. The NPQ reports scores patient and/or observer responses in terms of 20 symptom clusters: inattention, hyperactivity-impulsivity, learning problems, memory, anxiety, panic, agoraphobia, obsessions and compulsions, social anxiety, depression, mood instability, mania, aggression, psychosis, somatization, fatigue, sleep, suicide, pain and substance abuse. The NPQ is reliable (patients tested twice, patient-observer pairs, two observers) and discriminates patients with different diagnoses. Scores generated by the NPQ correlate reasonably well with commonly used rating scales, and the test is sensitive to the effects of treatment. The NPQ is suitable for initial patient evaluations, and a short form is appropriate for follow-up assessment. The availability of a comprehensive computerized symptom checklist can help to make the day-to-day practice of psychiatry, neurology and neuropsychology more objective.

Acknowledgements, Disclosures

The Neuropsych Questionnaire and related instruments were developed at The North Carolina Neuropsychiatry Clinics in Chapel Hill and Charlotte by Dr Gualtieri. Dr Gualtieri has conducted clinical trials on behalf of Astra-Zeneca, Bristol-Myers Squibb, Celltech, Cephalon, Eli Lilly, Glaxo-Smith-Kline, Medeva, Organon, Shire, Wyeth-Ayerst, and UCB. He has been a speaker for and/or consultant to Eli Lilly, GSK, Pfizer, Shire and Wyeth. This research was supported by North Carolina Neuropsychiatry, PA, in Chapel Hill and Charlotte. No external support was sought or received on behalf of this research.

In prior publications, we have recommended a solution to two problems in the clinical practice of psychiatry: that patient evaluation more should be more objective, and based on more than simply a clinical interview; and that the day-to-day practice of psychiatry should be more procedure-oriented. To these ends, we proposed that computerized neurocognitive testing was potentially useful in the evaluation and management of patients with brain injury (1), depression (2), schizophrenia and bipolar disorder (3), mild cognitive disorder and dementia (4) and ADHD (5).

Computer technology also has the potential to improve the efficiency of data gathering with respect to patients' subjective complaints. The Neuropsych Questionnaire, which we shall describe, is capable of capturing data that would ordinarily require the administration of several rating scales and symptom checklists. It is a procedure that generates quantitative data about the patient's status at the first evaluation visit, and, in a shorter form, at every follow-up visit.

In clinical research the systematic capture and quantitative analysis of psychiatric symptoms is done by using rating scales and questionnaires (RS). Conventional RS's are paper-and-pencil jobs that take time to administer and to score. If RS's could be administered electronically, however, clinicians might be inclined to use them more frequently. Capturing systematic and quantitative data about patients' symptoms can have positive ramifications on patient outcome (6) and quality assurance review (7)

Conventional RS's are inexpensive, quick and simple to use. Ideally, they capture all of the symptoms or signs of a given condition; if so, they are systematic. The same or similar rating scales can be given to patients and to important others (parents, spouses, teachers, clinicians, etc), permitting independent or concurrent assessment. Because RS's address key problems, changes in scores are taken to reflect clinically meaningful change; improvement, for example, when the score goes down, deterioration if the score goes up, "remission" if the score falls below a certain benchmark. Although there are hundreds, if not thousands of RS's in the medical literature, only a few are widely used. RS's therefore allow for uniformity of assessment and comparability of results in different clinical sites.

Why, then, aren't RS's used more frequently by practitioners? Not because of their conceptual and psychometric weakness, although there is no shortage of those (8): the problem of rater bias, "halo effects," "leniency error," regression to the mean and the "error of central tendency." In contrast to medical and psychological tests, RS are inherently subjective. They are essentially about giving a numerical value to a qualitative state, and they depend on the ability of the informant to understand the question and his inclination to disclose information. Many RS have a problem with poor correlation between rated and objectively observed behavior (9). Different RS have different metrics. A score of 20 indicates mild depression on the Beck depression inventory and severe depression on the Hamilton depression rating scale. Twenty is a pathological score on the Conners Parent-Teacher Questionnaire but a normal score on the Brown ADD scales. Not that any of this matters much, it seems. In practice, clinicians and investigators simply use their favorite scales, without regard to their psychometric properties (10).

Of greater concern to practitioners, though, are the practical problems of RS. A depression RS is appropriate to a clinical trial of patients with depression. But what RS should one use to discover that the patient is depressed in the first place? Comprehensive symptom inventories like the PAI and the BASC, and semi-structured interviews, like the SCID and the SADS and the MINI are expensive, time-consuming and hard to score.

Even in areas where RS technology is well developed, like depression, anxiety and ADHD, different RS emphasize different aspects of the condition. A good many of the questions on the venerable Hamilton RS for depression are about sleep and anxiety, for example, while the Beck depression inventory emphasizes cognitive symptoms of depression. Does that mean one should use both scales?

Because neuropsychiatric patients often have mixed disorders, or comorbid disorders, this rationale would lead one to use RS for the other conditions as well. But to deal with the content validity problem, one would have to use two or three RS for every comorbid disorder. That leads to a proliferation of paper that is virtually geometric. Patient response time and clinician scoring time would grow apace. There must be a better way to deal with the disadvantages of RS than simply multiplying RS.

The various disadvantages and weakness of RS are outweighed, however, by the importance of being systematic in one's approach to evaluation. Psychiatric RS may be inherently subjective, but being objective about subjective states is the essence of being a good clinician. So, we developed the Neuropsych Questionnaire to capture the advantages of RS technology, and to minimize the inefficiencies and costs of conventional RS.

DEVELOPMENT OF THE NEUROPSYCH QUESTIONNAIRE

We developed the Neuropsych Questionnaire for day-to-day use in our clinics. Its purpose is to inquire after the presence and intensity of symptoms of a wide range of neuropsychiatric disorders, to score patient responses and to collect them in the appropriate clinical scales, to generate a report and to save the results to a central database.

Because the NPQ is administered on a PC, it is a quick test to administer. Two hundred or so questions can be asked and answered in about 15 minutes. Because it is available online, the patient can complete the test at home, prior to his or her visit. Interested parties, spouses, parents, children, teachers, caregivers can respond to the questionnaire as well, without having to accompany the patient to the office. This generates concurrent data about the patient's condition from the perspective of relevant observers.

The NPQ was not developed as a diagnostic test, any more than any RS is a diagnostic test. It simply presents the opinions of a patient (and others) about the patient's clinical state at a point in time. Therefore, the validity of the questionnaire scores is a matter for the clinician to evaluate. If the NPQ report indicates that the patient scores in the severe range on all of the depression items, for example, that clearly merits the physician's attention. If the scores are low for depression, but the patient is clearly depressed during the examination, that also merits attention. It calls attention to the patient's appreciation of his or her problem, or at least his willingness to admit to it. If a patient and spouse generate similar reports, that is re-assuring; if their reports are disparate, that also can be useful information.

The NPQ aims to complement the clinical assessment of the neuropsychiatric patient. PC and internet technology generate quantitative data that enriches the psychiatric interview. It alleviates the problem of having to inquire, arduously, after numerous potential problems, and allows the clinician to spend more time exploring the meaning of the patient's complaints.

The NPQ was designed to be an initial assessment instrument. As such, asking 200 questions was not inappropriate. The PAI, for example, asks more than 350 questions, and the MMPI more than 500. A long questionnaire, however, is not appropriate for routine follow-up. Analysis of the NPQ, therefore, led to the development of a short form (NPQ-SF), with only 45 questions, that can be administered on line in about 5 minutes, and is suitable for follow-up visits.

ITEM SELECTION

The initial selection of items was based on a chart review of presenting symptoms made by patients, and in their own words. This review yielded a list of 439 symptoms. The list was augmented by a review of a number of rating scales and psychological instruments used in the

clinics, with special attention to the RS used in clinical trials. They generated 263 symptoms. Eliminating duplication yielded 207 symptom questions in the adult version of the scale and 201 in the pediatric version.

The numbers could be reduced because so many RS items are redundant. Questionnaires about disordered sleep, for example, appear on scales for depression, anxiety, mania, PTSD, etc. Even with reduction, however, there is 75% concordance between items on the NPQ and items on the following RS:


Table 1. Correspondence Between the NPQ Items and Other RS

	#ITEMS	NPQ	%
Brief Psychiatric Rating Scale	24	17	0.71
Hamilton Rating Scale for Depression	17	15	0.88
Montgomery Asberg Depression Rating Scale	10	10	1.00
Zung Self Rating of Depression Scale	20	16	0.80
Davidson Trauma Scale	17	14	0.82
ADHD Rating Scale	18	11	0.61
Hamilton Rating Scale for Anxiety	14	12	0.86
Beck Depression Inventory	21	12	0.57
Beck Anxiety Inventory	21	16	0.76
Young Mania Rating Scale	11	6	0.55
Symptom Checklist - 90	90	64	0.71

ITEM PRESENTATION, SCALING AND SCORING

The wording of the items was reduced to the simplest possible terminology, using, whenever possible, words and phrases from patients themselves. The presentation was standardized:


Figure 1. Item Presentation



The symptom, expressed in the simplest possible form, is presented in bold print. The answer grid is always the same: "not a problem," "a mild problem," "a moderate problem" or "a severe problem." This makes it easy for the subject to respond, and it reduces test time considerably.

Before the questions appear, the subject is instructed on how to answer (see Figure 2).

Figure 2. Instructions on How to Respond



The respondent can specify, at the beginning of the test, the time span that is covered by the questionnaire: today, the past few days, the past week, the past couple of weeks, the last month, the past six months, the past year, ever in your life. (The default is “the past couple of weeks.”) The identity of the respondent is also entered at the beginning of the test (patient, husband, wife, son, daughter, mother, father, other relative, friend, caregiver, teacher) and listed on the report. The questions are posed in a person and gender specific way (e.g., “Fidgety, I can’t sit still,” “Fidgety, he can’t...” or “Fidgety, she can’t...”). If the patient is less than eighteen years old, the pediatric questionnaire is administered; eighteen and older take the adult version..

RS technology generally recommends using “anchor points” to describe to the rater where a response should lie, in the most specific terms possible. Anchor points are believed to improve the reliability of a RS. Anchor points would be unwieldy in this format; they would increase reading time. Reliability of the NPQ is achieved through item redundancy.

The optimal number of points on a RS has been the subject of earnest debate; the idea that seven-point scales are optimal dates from 1924 (11) but others have suggested better results with finer-grained scales (10-20 points) (12). Preston et al, (13) demonstrated that scales with 7, 8 or 9 points were more reliable than scales with 2, 3 or 4 points. But it has also been represented that “the number of response categories does not materially affect the cognitive structure derived from the results (14). Simplicity, and ease of administration, led us to select a four-point scale. The idea was that reliability would be preserved by reducing administration time for each item, and thus permitting the inclusion of multiple and even redundant items.

Each item is scored as 0-1-2-3. Items are then clustered into scales; for example, all the items that address the specific problem of depression, anxiety, memory, etc. For example, 22 items speak to the problem of memory impairment. The patient’s scores on these 22 items are averaged. If the average score is 1.23, it is multiplied by 100 to eliminate the decimal point. So, the patient’s memory score would be reported as 123. The highest score someone might receive on a scale is 300; that would indicate that he or she had marked every item in the relevant scale as “a severe problem.” The lowest score one might get is zero; every item in the scale is scored as “not a problem.”

The items in the NPQ are not weighted. That is, every item in a scale is considered as important as every other. This created some anomalies. For example, in the beta version of the NPQ, the item “mind going blank” was deemed as important to the measurement of anxiety as “feeling nervous” or “feeling anxious.” The problem was addressed in the item analysis; items that were infrequently cited by patients, or that failed to generate sufficient weight in the factor analysis, or that correlated poorly with the scale score, were dropped from that particular scale. In the case of anxiety, “mind going blank” was eliminated but “feeling nervous” and “feeling anxious” were retained.

The test also computes an “average symptom cluster,” which is the average score of *all* the items on the test. Theoretically, that ought to be a like a global score. It may or may not prove to be a useful metric.

EVALUATION OF THE BETA VERSION OF THE NPQ

The NPQ was administered to 814 adults, age 18-80 (mean age, 36.6, SD 14.1). Forty-five per cent. of the sample were males, and 90% were white. Mean education was 14.5 years. A wide range of neuropsychiatric diagnoses were represented; the numbers in Table 2 add up to more than 814, because many patients had multiple diagnoses.

Table 2. Diagnoses of the Beta Sample

DIAGNOSIS	
Depression	210
ADHD	206
Anxiety	102
Brain Injury	86
Normal	80
Bipolar Disorder	75
Anxiety & Depression	29
PTSD	23
Mild Cognitive Impairment	14
Schizophrenia	10
Chronic Fatigue	5
Conversion Disorder	5
OCD	4
Social Anxiety	3

The patient diagnoses in the various sections of this paper were conferred by treating clinicians on the basis of DSM-IVtr criteria, and were reviewed by the author.

SCALE SELECTION

The items and the scale structure from the beta version of the NPQ were adjusted after data from 814 adult patients were analyzed. The final version of the NPQ includes a number of new, experimental items, requested by participating clinicians (suicide, pain, substance abuse). The final version of the adult NPQ has 207 questions that represent 20 different symptom clusters, or scales. The pediatric NPQ has 201 questions and 20 scales. The list of 207 items in the adult NPQ and the scales to which they contribute is given in Appendix 1.

The initial selection of scales was based on the frequency of disorders and symptom clusters that present at the Neuropsychiatry Clinics. Factor analysis led to adjustments in the scale structure. Principal component analysis generated a sixteen-factor solution that accounted for 57% of the variance in the sample. The first factor included depression, anxiety and mood instability, and accounted for 28% of the variance. Discrete factors emerged that defined ten additional scales: obsessive-compulsive, hyperactive-impulsive, psychotic, mania, somatization, learning problems, panic, social anxiety, aggression and disordered sleep. Maximum likelihood extraction generated differential factors for panic and agoraphobia.

Discrete factors did not emerge for the scales of attention or fatigue. These scales were deemed clinically important, however, and were retained. Participating clinicians also suggested additional items to add to the NPQ that comprised scales for pain, substance abuse and

suicidality. These were added as experimental scales, subject to future analysis. The 20 scales in the adult NPQ are given in Table 3.

The scales refer to symptom clusters and not to DSM or ICDM diagnoses. That was a considered decision. The NPQ is a measurement instrument, not a diagnostic instrument. Patients' complaints and the opinions of observers are valuable data, but diagnosis is a medical exercise.

Table 3. Twenty Scales in the Adult NPQ

BETA VERSION SCALES	FINAL SCALES
Inattention	Inattention
Hyperactivity-Impulsivity	Hyperactivity-Impulsivity
Learning problems	Learning problems
Memory problems	Memory problems
Anxiety	Anxiety
Panic	Panic
	Agoraphobia
Obsessions, compulsions	Obsessions, compulsions
Social anxiety	Social anxiety
Depression	Depression
Mood instability	Mood instability
Mania	Mania
Aggression	Aggression
Psychosis	Psychosis
Somatization	Somatization
Fatigue	Fatigue
Disordered sleep	Disordered sleep
	Suicide
	Pain
	Substance abuse

ITEM RE-CLASSIFICATION AND INTERNAL CONSISTENCY

The internal consistency of each scale was assessed by Cronbach's alpha. The data indicate a high degree of internal consistency for all of the new scales. High alphas (> 0.90) indicate redundancy among the items in several of the scales.

Table 4. Internal Consistency of the Adult NPQ Scales

Cronbach's alpha N= 814		
		alpha
ATT	Inattention	0.911
HA-IMP	Hyperactivity-Impulsivity	0.826
LPX	Learning problems	0.895
MEM	Memory problems	0.942
ANX	Anxiety	0.92
PANIC	Panic	0.866
AGORA	Agoraphobia	0.87
OCD	Obsessions, compulsions	0.915
SAD	Social anxiety	0.882
DEP	Depression	0.95
MS	Mood instability	0.925
MANIA	Mania	0.788
AGG	Aggression	0.884
PSYCHO	Psychosis	0.838
SOM	Somatization	0.938
FATIG	Fatigue	0.918
SLEEP	Disordered sleep	0.856


TEST-RETEST RELIABILITY: PATIENTS TESTED TWICE

Seventy five neuropsychiatric patients were administered the NPQ on two occasions within three months. The diagnoses were mixed (depression, 16; brain injury, 10; bipolar disorder, 9; anxiety, 8; chronic pain, 5; ADHD, 4; PTSD, 4; MCI or early dementia, 3; schizophrenia, 2; mixed disorders accounting for the rest). Mean age was 42.4 (18-72) and years of education 14.3 (10-18). Forty four were female and 67 were white.

Table 5. Test-Retest Reliability for Patients Taking the Adult NPQ

	Patient-Patient N = 75	
	r	P<
ATTENTION	0.70	0.00000
HA-IMP	0.66	0.00000
LPX	0.80	0.00000
MEM	0.74	0.00000
ANX	0.73	0.00000
PANIC	0.67	0.00000
AGORA	0.77	0.00000
OCD	0.88	0.00000
SAD	0.77	0.00000
DEP	0.80	0.00000
MS	0.76	0.00000
MANIA	0.59	0.00000
AGG	0.70	0.00000
PSYCHO	0.80	0.00000
SOM	0.77	0.00000
FATIG	0.72	0.00000
SLEEP	0.54	0.00000
ASC	0.85	0.00000
average	0.74	
min	0.54	
max	0.88	

Figure 3. NPQ Scores on Two Successive Administrations




INTERRATER RELIABILITY: PATIENT-OBSERVER PAIRS

Eighty-two neuropsychiatric patients and their closest relation were administered the NPQ on the same day, but separately, in two separate rooms. The diagnoses were mixed (depression, 15; brain injury, 17; bipolar disorder, 4; chronic pain, 4; ADHD, 3; PTSD, 2; MCI or early dementia, 1; schizophrenia, 1; mild mental retardation, 3; mixed disorders accounting for the rest). Mean age was 38.2 (18-68) and years of education 14.2 (8-20). Twenty-five were female and 71 were white.

Table 6. Interrater Reliability, Patient-Observer Pairs

	Patient-Observer N = 82	
	r	P<
ATTENTION	0.39	0.00032
HA-IMP	0.63	0.00000
LPX	0.34	0.00171
MEM	0.49	0.00000
ANX	0.62	0.00000
PANIC	0.63	0.00000
AGORA	0.63	0.00000
OCD	0.51	0.00000
SAD	0.59	0.00000
DEP	0.57	0.00000
MS	0.56	0.00000
MANIA	0.34	0.00158
AGG	0.58	0.00000
PSYCHO	0.60	0.00000
SOM	0.74	0.00000
FATIG	0.54	0.00000
SLEEP	0.43	0.00005
ASC	0.62	0.00000
average	0.54	
min	0.34	
max	0.74	

Figure 4. NPQ Scores, Patients and Observers




SENSITIVITY TO TREATMENT

24 patients with various neuropsychiatric disorders were administered the NPQ on two occasions, once prior to treatment, and then after treatment. Mean patient age was 36.3 (20-55) and years of education 14.3 (8-20). Fourteen patients were female and 22 were white. Diagnoses included depression (6), BPAD (5), ADHD (4), anxiety (2), OCD (2), PTSD (2) and brain injury (2).

Figure 5. NPQ Before and After Treatment

SQ BEFORE AND AFTER TREATMENT



THE NPQ IN DIFFERENT DIAGNOSTIC GROUPS

NPQ results were available for 809 neuropsychiatric patients, with reliable data on diagnosis and treatment response. After independent chart review, the following records were selected. The remaining patients had mixed or ambiguous diagnoses. The patients were divided into two groups: new patients who had not yet been treated, and patients whose treatment was deemed successful by the treating physician. Partial responders, or patients whose treatment was not yet completed, were excluded. The figures also include data from 80 normal controls.

Figure 6. 170 Patients with Depression, 112 Pre-treatment, 58 Treated Successfully.




Figure 7. 153 Patients with ADHD, 113 Pre-treatment, 40 Treated Successfully.




Figure 8. 78 Patients with Anxiety, 49 Pre-treatment and 29 Treated Successfully.





Figure 9. 58 Patients with Bipolar Disorder, 26 Pre-treatment, 32 Treated Successfully.



THE SHORT FORM OF THE NEUROPSYCH QUESTIONNAIRE (NPQ-SF)

The NPQ only takes 15 minutes, but a shorter questionnaire would be more appropriate for follow-up visits. The fact that many of the items in the NPQ are redundant made it relatively easy to develop a shorter form of the questionnaire. The goal was to cover the most important scales in a questionnaire that contained 45 items, and that could be administered in less than 5 minutes.

The process of item selection was based on factor loadings, intercorrelation analysis and symptom frequency in patients with known disorders. Several scales from the NPQ were not used in the short form. This was largely a clinical decision. "Learning problems" is a scale more pertinent to a diagnostic evaluation than to follow up. The clinical problem of agoraphobia is not commonly met with in our patient population. Patients with social anxiety disorder, schizophrenia, OCD and BPAD seem to be less forthcoming about their core symptoms, and more likely to complain of problems with attention, fatigue, anxiety, etc.

The scale scores for the NPQ-SF are highly correlated with the NPQ scale scores (r 0.89-0.99).

Table 7. Correlation between the NPQ and the NPQ-Short Form.

SHORTFORMS	ATT	HA-IMP	MEM	ANX	PANIC	DEP	MS	AGG	SOM	FATIG	SLEEP
ASC	0.73	0.67	0.79	0.85	0.72	0.89	0.83	0.64	0.73	0.73	0.62
ATT-SF	0.96	0.60	0.76	0.59	0.35	0.57	0.58	0.31	0.45	0.55	0.45
HA-SF	0.63	0.98	0.52	0.78	0.48	0.56	0.73	0.49	0.42	0.41	0.50
MEM-SF	0.82	0.49	0.89	0.54	0.37	0.57	0.53	0.35	0.49	0.55	0.45
ANX-SF	0.60	0.76	0.56	0.99	0.66	0.81	0.83	0.49	0.60	0.63	0.73
PANC-SF	0.34	0.46	0.40	0.70	0.97	0.61	0.57	0.42	0.60	0.45	0.44
DEP-SF	0.60	0.50	0.60	0.81	0.55	0.95	0.73	0.44	0.69	0.86	0.72
MS-SF	0.57	0.67	0.53	0.81	0.52	0.73	0.97	0.62	0.50	0.56	0.52
AGG-SF	0.33	0.46	0.41	0.50	0.40	0.51	0.68	0.94	0.39	0.35	0.29
SOM-SF	0.45	0.36	0.54	0.55	0.48	0.61	0.48	0.34	0.92	0.69	0.56
FTG-SF	0.51	0.33	0.52	0.60	0.43	0.77	0.53	0.29	0.67	0.95	0.51
SLEEP-SF	0.44	0.46	0.45	0.70	0.42	0.65	0.51	0.29	0.56	0.53	0.94

The reliability of the NPQ-SF is almost as good as the NPQ. Test-retest reliability for the NPQ ranges from 0.54-0.80, average 0.71; for the NPQ-SF, 0.53-0.82. Interrater reliability for the NPQ, patient-observer pairs is 0.39-0.74interrater reliability

Table 8. Comparative Reliability of the NPQ and the NPQ-SF

NPQ	Patient-Patient N = 75	Patient-Observer N = 82	Two observers N =28
average	0.71	0.56	0.61
min	0.54	0.39	0.42
max	0.80	0.74	0.81
NPQ-SF			
average	0.69	0.55	0.54
min	0.53	0.39	0.33
max	0.82	0.74	0.76

The advantage of a longer questionnaire is that it is more reliable, but in this case, it is not much more reliable. Why not use the short form all the time, then? Clinicians can choose to do as they please, but we prefer the NPQ for evaluations and re-evaluations, and the short form for follow-ups. The NPQ is much more comprehensive, and even though patients with some disorders may not be forthcoming, or insightful concerning their symptoms, their close relations are likely to be more accurate in their assessments.

AVAILABILITY OF THE NPQ

The NPQ and the NPQ-SF are available without charge to qualified psychiatrists, neurologists and psychologists through our website (see Box). All one needs is a PC and a high-speed Internet connection. The program works best on Mozilla, a free internet browser. A report is generated as soon as the test is completed. At some point, we hope that practitioners will be able to store the data they generate in a central storage facility, as we do, and that the program will be able to generate serial data. For now, though, the only record is the hard copy report one prints out when the test is done.

ACCESSING THE NEUROPSYCH QUESTIONNAIRE

www.ncneuropsych.com > Online Assessment > Start Online Assessment

Administrator Name: doctor

Password: doctor

REFERENCES

1. Gualtieri, CT, Johnson LG & Benedict, KB. Psychometric and Clinical Properties of a new Computerized Neurocognitive Screening Battery. Abstract, ANPA Annual Meeting, Bal Harbor, Florida, 2004
2. Gualtieri, CT, Johnson, LG & benedict, KB. Neurocognition in Depression: Patients on and off Medication, Compared to Normal Controls. *J Neuropsych Clin Neuroscience*, 18, 217-225, 2006.
3. Gualtieri, CT, Johnson, LG. A Computerized Neurocognitive Test Battery for Studies of Schizophrenic and Bipolar Patients. Abstract, 13th Biennial Winter Workshop on Schizophrenia Research, Davos, 2006. *Schiz. Research*, 81, 122, 2006a.
4. Gualtieri, CT, Johnson, LG. Neurocognitive Testing Supports a Broader Concept of Mild Cognitive Impairment. *J Alz Rltd Dem*, 20, 359-366, 2006b.
5. Gualtieri, CT, Johnson, LG. Efficient Allocation of Attentional Resources in Patients with ADHD: Maturational Changes from Age 10 to 29. *J Attention Dis*, 9, 534-542, 2006c.
6. Slade, M, McCrone, P, Kuipers, E, Cahill, S, Parabiaghi, A, Priebe, S, Thornicroft, G. The Use of Standardized Outcome Measures in Adult Mental Health Services: Randomised Controlled Trial. *Br J Psychiatry*, 189, 330-336, 2006.
7. Kesselheim, AS, Ferris, TG, Studdert, DM. Will Physician-Level Measures of Clinical Performance Be Used in Medical Malpractice Litigation? *JAMA*, 15, 1831-1834, 2006.
8. Bagby RM, Ryder AG, Schuller DR, Marshall MB The Hamilton Depression Rating Scale: has the gold standard become a lead weight?. *Am J Psychiatry*, 61, 2163-77, 2004.
9. Streiner, DL & Norman, GR. *Health Measurement Scales A Practical Guide to Their Development and Use*. Second Edition. Oxford Univ Press, Oxford, 1995.
10. Mowbray RM, *Psychometrics & Psychopharmacology*, pp 129-182, in GD Burrows & JS Werry, *Advances in Human Psychopharmacology*, JAI Press, Greenwich, CT, 1981
11. Symonds, PM. On the Loss of Reliability in Ratings due to the Coarseness of the Scale. *J Exp Psychol* 17 456-461, 1924.
12. Garner, WR. Rating scales, discriminability, and information transmission. *Psychol Rev* 67:343-52, 1960.
13. Preston, CC, Colman, AM. Optimal number of response categories in rating scales: reliability, validity, discriminating power, and respondent preferences. *Acta Psychol (Amst)* 104, 1-15, 2000.
14. Schutz, HG, Rucker, MH. Variable Configurations across Scale Lengths: An Empirical Study. *Educ Psychol Measurement* 35, 319-24, 1975.

